Sanuwave Health (NASDAQ:SNWV) Posts Earnings Results, Misses Estimates By $0.03 EPS

Sanuwave Health (NASDAQ:SNWV) posted its quarterly earnings data on Tuesday. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.03), FiscalAI reports. Sanuwave Health had a net margin of 26.64% and a negative return on equity of 141.56%. The company had revenue of $9.62 million for the quarter, compared to analysts’ expectations of $9.60 million.

Sanuwave Health Price Performance

NASDAQ SNWV traded up $0.04 during trading hours on Tuesday, reaching $16.04. The company’s stock had a trading volume of 155,073 shares, compared to its average volume of 73,070. The firm’s 50-day moving average price is $19.33 and its 200-day moving average price is $25.85. The company has a quick ratio of 1.05, a current ratio of 1.38 and a debt-to-equity ratio of 10.08. Sanuwave Health has a 1 year low of $15.35 and a 1 year high of $46.58. The company has a market capitalization of $137.94 million, a price-to-earnings ratio of -100.24 and a beta of 1.37.

Institutional Trading of Sanuwave Health

Large investors have recently added to or reduced their stakes in the company. Legal & General Group Plc bought a new stake in Sanuwave Health in the 2nd quarter worth approximately $26,000. BNP Paribas Financial Markets bought a new stake in Sanuwave Health in the 2nd quarter worth approximately $46,000. Russell Investments Group Ltd. bought a new position in shares of Sanuwave Health during the 3rd quarter valued at approximately $67,000. New York State Common Retirement Fund bought a new position in shares of Sanuwave Health during the 2nd quarter valued at approximately $102,000. Finally, JPMorgan Chase & Co. bought a new position in shares of Sanuwave Health during the 2nd quarter valued at approximately $109,000. Institutional investors own 42.53% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. Wall Street Zen cut Sanuwave Health from a “buy” rating to a “hold” rating in a research report on Saturday, March 28th. Zacks Research cut Sanuwave Health from a “hold” rating to a “strong sell” rating in a research report on Monday, March 30th. Roth Mkm reissued a “buy” rating and issued a $47.00 price target (down from $53.00) on shares of Sanuwave Health in a report on Monday, March 30th. Finally, Weiss Ratings raised Sanuwave Health from a “sell (d-)” rating to a “hold (c-)” rating in a report on Friday, March 27th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $51.00.

About Sanuwave Health

Sanuwave Health, Inc is a medical technology company specializing in the development and commercialization of non-invasive acoustic wave therapies designed to stimulate tissue regeneration and accelerate healing. The company’s proprietary Extracorporeal Pulse Activated Technology (EPAT) delivers focused acoustic pressure waves to injured or chronic wound sites, activating the body’s natural repair mechanisms. Sanuwave’s primary therapeutic areas include advanced wound care for diabetic and venous ulcers, as well as orthopedic and musculoskeletal conditions.

The company’s lead product, the dermaPACE® system, holds clearance from the U.S.